Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial

Primer Autor
Raubenheimer, Peter J.
Co-autores
Cushman, William C.
Avezum, Alvaro
Basile, Jan
Conget, Ignacio
Dagenais, Gilles
Hoover, Anastasia
Jansky, Petr
Lanas, Fernando
Leiter, Lawrence A.
Lopez-Jaramillo, Patricio
Pogosova, Nana
Probstfield, Jeffrey
Rao-Melacini, Purnima
Ryden, Lars
Sheu, Wayne H-H
Temelkova-Kurktschiev, Theodora
Gerstein, Hertzel C.
Título
Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial
Editorial
WILEY
Revista
DIABETES OBESITY & METABOLISM
Lenguaje
en
Resumen
Aim To assess the occurrence of atrial fibrillation or atrial flutter (atrial arrhythmias [AA]) in patients with type 2 diabetes treated with once-weekly subcutaneous dulaglutide versus placebo. Materials and Methods Patients without electrocardiographic (ECG)-confirmed AA at baseline and randomized in the REWIND trial were assessed for the development of AA based on an annual ECG. Additional analyses included whether dulaglutide compared with placebo reduced the composite outcome of AA or death, AA or cardiovascular death, AA or stroke and AA or heart failure. Results Among 9543 participants (mean age 66 +/- 7 years, with cardiovascular risk factors and 31% with previous cardiovascular disease) without AA at entry in the trial, 524 patients (5.5%) had at least one episode of AA during the median 5.4 years of follow-up. Incident AA occurred in 269 of the 4769 participants allocated to dulaglutide (5.6%), at a rate of 10.7 per 1000 person-years, versus 255 of the 4774 allocated to placebo (5.3%), at a rate of 10.5 per 1000 person-years (P = .59). There was also no effect of dulaglutide on the composite outcome of AA and death or AA and heart failure. Conclusion This post hoc analysis of data from the REWIND trial showed that treatment with dulaglutide was not associated with a reduced incidence of AA in this at-risk group of patients with type 2 diabetes.
Tipo de Recurso
artículo original
doi
10.1111/dom.14634
Formato Recurso
PDF
Palabras Claves
atrial fibrillation
atrial flutter
dulaglutide
glucagon-like peptide-1 receptor agonists
type 2 diabetes
CARDIOVASCULAR OUTCOMES
EXPLORATORY ANALYSIS
INDEPENDENT RISK
METAANALYSIS
MELLITUS
EVENTS
HEART
PREVALENCE
INCRETIN
COHORT
Ubicación del archivo
http://dx.doi.org/10.1111/dom.14634
Categoría OCDE
Endocrinología y Metabolismo
Materias
fibrilación auricular
aleteo auricular
dulaglutida
agonistas del receptor del péptido 1 similar al glucagón
diabetes tipo 2
RESULTADOS CARDIOVASCULARES
ANÁLISIS EXPLORATORIO
RIESGO INDEPENDIENTE
METANÁLISIS
MELLITUS
EVENTOS
CORAZÓN
PREVALENCIA
INCRETINA
COHORTE
Disciplinas de la OCDE
Endocrinología y Metabolismo (Incluye Diabetes, Hormonas)
Sistema Cardiovascular y Cardiaco
Otros Temas de Medicina Clínica
Versión del recurso (Recomendado-único)
version publicada
Tipo de ruta
hibrida
verde
Access Rights
metadata
Derechos de acceso
metadata
Id de Web of Science
WOS:000746220400001
Título de la cita (Recomendado-único)
Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial
Página de inicio (Recomendado-único)
704
Página final (Recomendado-único)
712
Identificador del recurso (Mandatado-único)
artículo original
Condición de la licencia (Recomendado-repetible)
0
Colecciones
Colección Publicaciones Científicas
Estadísticas del documento
0 visitas
Métricas externas
Altmetric
Dimensions